Hologic, Inc. ( HOLX Quick Quote HOLX - Free Report) recently launched its latest CE-marked Fluent fluid management system in Europe. Notably, the system has been designed to include features to enable healthcare professionals to perform simpler and more effective fluid management during hysteroscopic procedures.
For investors’ note, the Fluent fluid management system is equipped with an integrated MyoSure controller, which can maximize the MyoSure system’s performance with Fluent’s fluid and vacuum systems.
With the latest launch, Hologic aims to strengthen its GYN Surgical products business on a global scale.
Significance of the Launch
The Fluent fluid management system is expected to provide consistent intrauterine pressure and accurate fluid deficit readings to clinicians. Further, its technology has been designed to aid in maintaining consistent intracavity pressure and uterine distention, and measure fluid deficit readings.
The Fluent system has been designed such as to not only simplify hysteroscopic operations (operations of the inside of the cervix and uterus) but also help optimize workflow.
Industry Prospects Per a report by Grand View Research, the global fluid management and visualization systems market was valued at $8.39 billion in 2019 and is anticipated to grow at a CAGR of 5.1% between 2020 and 2027. Factors like increasing number of minimally invasive surgeries and technological advancements in fluid management system are expected to drive the market.
Given the market potential, the recent launch is expected to significantly boost Hologic’s GYN Surgical business globally.
Notable Developments in GYN Surgical Arm
Hologic has been witnessing a series of developments in its GYN Surgical business over the past few months.
The company, in November 2020, launched the Omni Suite, which is a comprehensive surgical offering designed to optimize diagnostic and operative hysteroscopy.
The same month, during its fiscal fourth-quarter earnings call, Hologic observed faster-than-expected business recovery in this segment. Further, the company completed the buyout of Acessa Health Inc, a privately held player in minimally invasive treatment for fibroids. Notably, the acquisition was announced in August 2020.
Shares of the company have gained 40.9% in the past year compared with the
industry and the S&P 500’s 26.6% and 20.7% growth, respectively. Zacks Rank & Other Key Picks
Currently, Hologic flaunts a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space are
Omnicell, Inc. ( OMCL Quick Quote OMCL - Free Report) , IDEXX Laboratories, Inc. ( IDXX Quick Quote IDXX - Free Report) and Patterson Companies, Inc. ( PDCO Quick Quote PDCO - Free Report) .
Omnicell’s long-term earnings growth rate is estimated at 16%. The company presently sports a Zacks Rank #1. You can see
the complete list of today’s Zacks #1 Rank stocks here.
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
Patterson’s long-term earnings growth rate is estimated at 11.1%. The company presently carries a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>